Dave Schrader
Dave Schrader is the Vice President, Quality and Compliance of Lumos Pharma. He brings twenty years of experience holding various quality and compliance roles throughout his career in the pharmaceutical industry. Prior to the merger with Lumos Pharma, he held various roles of increasing responsibility in the quality department at NewLink Genetics. As part of...Read More
Thomas A. Raffin
Thomas A. Raffin, M.D., has served as a member of the Board since 1999 and has been the Board’s Lead Independent Director since October 2010. Dr. Raffin has spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics....Read More
Kevin Lalande
Kevin Lalande is a Founding Partner of Santé Ventures, an early-stage life science and healthcare venture capital company based in Austin, Texas. Prior to Santé, Kevin spent seven years with Austin Ventures, a prominent venture…Read More
Chad A. Johnson
Chad A. Johnson, JD, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) since March 2018. Mr. Johnson is currently Senior Counsel at BASF. From May 2017 to October 2022, Mr. Johnson served as General Counsel at Stine Seed Company. From May 2015 to April 2017, Mr. Johnson was the Assistant Corporate...Read More
Lota S. Zoth
Lota S. Zoth, CPA, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) and Chair of our Audit Committee since November 2012. Ms. Zoth currently also serves on the Board of Directors of two other biopharmaceutical organizations, including Zymeworks Inc. (NYSE:ZYME) – Board Chair and Audit Committee Chair, and Inovio Pharmaceuticals (NASDAQ:INO)...Read More